Servier India, a subsidiary of French pharmaceutical company Servier Group, has launched a biomarker testing initiative with India’s genomic laboratories MedGenome and Strand Life Sciences, for two specific types of blood cancers.

“A customized panel of biomarker tests for Acute Myeloid Leukaemia (AML), an aggressive blood cancer and Cholangiocarcinoma (CCA), a rare bile duct cancer, is launched across India at subsidised rates making these advanced diagnostics more affordable and accessible,” a note from Servier said, adding that the panel will be available to healthcare professionals across private and government sectors. “Specifically, IDH1 and IDH2 mutation testing for AML and CCA, will be available free of cost for the government sector,” it said.

The biomarker testing initiative ai

See Full Page